TP53 is the most frequently mutated gene in human cancers and is thus one of the most studied (72,500 publications, pubmed August 2014). For 25 years it was thought that human TP53 expressed only one protein, p53. In 2005, we reported that the human TP53 gene expresses at least 12 p53 proteins (p53 isoforms) as a result of alternative splicing, alternative initiation of translation, and alternative promoter usage. 1 Each p53 isoform contains distinct protein domains. These p53 isoforms were also identified in mouse, zebrafish, and Drosophila, suggesting that they play important physiological roles since their expression is conserved through evolution. In normal tissue the human TP53 gene expresses the following isoforms in a tissue-dependent manner: p53a (canonical p53), p53b, p53g, D40p53a, D40p53b, D40p53g, D133p53a, D133p53b, D133p53g, D160p53a, D160p53b, and D160p53g. Only p53a is expressed in every tissue. However, p53a is never expressed alone; rather, several p53 isoforms are always coexpressed with p53a in normal human tissue. 1 We and others have analyzed p53 isoform expression in a large panel of cancer cell lines and normal cells derived from diverse tissue origins. None of the normal and cancer cell lines (epithelial or fibroblast) expressed only canonical p53 (p53a) and p53a was always co-expressed with several p53 protein isoforms at the cellular level. [1] [2] [3] [4] [5] [6] [7] A large body of evidence has now demonstrated that any changes in cell homeostasis activate a cellular response dependent on p53. Therefore, any anticancer drugs or treatments that affect cell homeostasis directly or indirectly activate p53 and trigger a p53-dependent cell response. In other words, the expression of wild-type (WT) TP53 gene determines whether a cell is going to survive, senesce, proliferate, differentiate, migrate, or die in response to cancer treatment. However, what is the so-called p53 protein? Is p53 only one protein (p53a) or a group of p53 isoforms? Which protein(s) encoded by the TP53 gene have the biological and biochemical activities attributed to p53? These questions are of paramount importance because the answers will have a profound impact on the treatment of cancer patients.
In a recently published article entitled "Modulation of p53b and p53g expression by regulating the alternative splicing of TP53 gene modifies cellular response," 8 we investigated whether p53 is a single protein, p53a, or a group of p53 protein isoforms including p53a. We determined that endogenous p53b and p53g protein expression can be induced by manipulating the alternative splicing process. To achieve this, we treated a panel of WT TP53 cell lines with a novel specific inhibitor of Cdc2-like kinases, TG003. Cdc2-like kinases regulate some alternative splicing pre-mRNA processes by phosphorylating particular splicing factors such as SRSF1 and SRSF3. Importantly, inhibition of Cdc2-like kinases does not abolish all alternative splicing events. We determined that inhibition of Cdc2-like kinases by TG003 or the knockdown of SRSF1 promotes the inclusion of TP53 exons 9b/9g and induces p53b and p53g protein expression. Using siRNA that specifically targeted TP53 exons 9b/9g with no effect on p53a expression, we established that endogenous p53b and p53g inhibit cell proliferation by promoting cell death in MCF7 cells grown under standard culture condition. Conversely, by combining TG003 and siRNA targeting specifically TP53 exons 9b/9g with no effect on p53a expression, we showed that endogenous p53b and p53g proteins promote proliferation of MCF7 cells upon inhibition of Cdc2-like kinases by TG003. Therefore, p53b and p53g have dual activities, promoting either death or proliferation of WT TP53 cells depending on the cellular context. Mechanistically, p53b and p53g form stable protein complexes with p53a on the DNA of p53-responsive promoters such that oligomers composed of p53b and p53a and oligomers composed of p53g and p53a regulate expression of different p53-responsive genes. The opposite activities of p53b and p53g isoforms observed in non-treated and TG003-treated cells may reflect the effect of TG003 on both the expression and Our data demonstrate that manipulation of endogenous p53b and p53g protein expression using a splicing factor inhibitor and/or siRNA targeting specifically TP53 exons 9b/9g, allows us to trigger different p53-mediated cell responses in a single cell line in a controlled way. This is consistent with previous data; we and others have previously shown that D40p53a and D133p53a oligomerize with p53a and regulate the p53-mediated cell response. 7 For the past 10 years, we and others have investigated whether p53 is a single protein, p53a, or a group of p53 isoforms using different animal models (zebrafish, Drosophila, mouse) and different normal and cancer cell lines derived from distinct human tissues. Irrespective of the cell lines or animal models used, all of the data consistently indicate that the cell fate decision in response to damage or cell signals is defined by the p53 isoforms. [6] [7] [8] [9] [10] Therefore, we can now assert that the protein generally called p53 is NOT a single protein, p53a, but is in fact an ensemble of different oligomers, each composed of distinct p53 protein isoforms. Each oligomer has a different intrinsic transcriptional activity and promoter specificity. Hence, the p53-mediated cell response would be defined by the sum of the activities of each p53 isoform oligomer. This would explain why manipulation of the cellular composition of p53 isoforms by small molecules can trigger opposite p53-dependent cell fate outcomes (repair/survival/proliferation or cell death) in the same cell type in response to the same treatment. It is thus imperative to decipher the mechanism of p53-isoform mediated cell fate decisions for efficient clinical application of anticancer drugs including the new p53-targeting drugs such as Nutlin, Prima, and Rita.
In light of the literature discussed here, p53 isoforms offer novel exciting perspectives in basic and translational research that I am convinced will revolutionize cancer treatment, improving patient quality of life and survival.
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